News
In a report released on July 30, Nicolas Pauillac from Kepler Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,500.00. The company’s shares closed yesterday at p1,418.00.
Despite the recent buzz, the effort to reduce animal testing in favor of NAMs has been underway for years. The VQN falls ...
Fierce Pharma Asia—GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy
GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...
GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...
Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...
2d
TipRanks on MSNGlaxoSmithKline Reports Strong Q2 2025 PerformanceGlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...
CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...
British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...
3d
Pharmaceutical Technology on MSNGSK’s speciality medicines soar while generals drop, Q2 results reveal"GSK’s speciality medicines soar while generals drop, Q2 results reveal " was originally created and published by ...
LONDON (AP) — LONDON (AP) — GSK plc (GSK) on Wednesday reported second-quarter earnings of $1.93 billion. The London-based company said it had profit of 94 cents per share. Earnings, adjusted for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results